Department of Health and Human Services February 20, 2020 – Federal Register Recent Federal Regulation Documents

Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics; Draft Guidance for Industry; Availability
Document Number: 2020-03426
Type: Notice
Date: 2020-02-20
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance entitled ``Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics.'' This guidance expands upon, consolidates, and supplements the recommendations on nonclinical immune system assessments provided across multiple guidance documents, most notably the International Conference on Harmonization (ICH) guidance for industry ``S8 Immunotoxicity Studies for Human Pharmaceuticals.'' The topics covered include various aspects of immune suppression, modulation, and stimulation. This guidance replaces the withdrawn guidance entitled ``Immunotoxicology Evaluation of Investigational New Drugs.''
Medical Imaging Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
Document Number: 2020-03424
Type: Notice
Date: 2020-02-20
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Medical Imaging Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
Document Number: 2020-03410
Type: Notice
Date: 2020-02-20
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pulmonary-Allergy Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Submission for OMB Review; Tribal Child Support Enforcement Direct Funding Request: 45 CFR 309-Plan (OMB #0970-0218)
Document Number: 2020-03354
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, Administration for Children and Families
The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF) is requesting a 3-year extension of the 45 CFR 309-Plan (OMB #0970-0218, expiration 3/21/2020). There are no changes requested to this form.
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2020-03343
Type: Notice
Date: 2020-02-20
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2020-03342
Type: Notice
Date: 2020-02-20
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Center for Scientific Review; Amended Notice of Meeting
Document Number: 2020-03341
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: 2020-03336
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: 2020-03335
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: 2020-03334
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Document Number: 2020-03333
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2020-03332
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings
Document Number: 2020-03331
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Document Number: 2020-03330
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
Compounding Animal Drugs From Bulk Drug Substances; Draft Guidance for Industry; Availability; Reopening of Comment Period
Document Number: 2020-03312
Type: Notice
Date: 2020-02-20
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the notice of availability that published in the Federal Register on November 20, 2019. In that notice, FDA requested comments on the draft guidance for industry (GFI) #256 entitled ``Compounding Animal Drugs from Bulk Drug Substances.'' FDA is reopening the comment period to update comments and to receive any new information.
HHS Notice of Committee Establishment, Notice of Intent To Convene, and Call for Nominations for the NIH Human Fetal Tissue Research Ethics Advisory Board for Fiscal Year 2020
Document Number: 2020-03302
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, Office of the Secretary
The U.S. Department of Health and Human Services (HHS) announces the establishment of, and intent to convene, the National Institutes of Health (NIH) Human Fetal Tissue Research Ethics Advisory BoardFY 2020 (Ethics Board or Board), as authorized by section 492A of the Public Health Service (PHS) Act, as amended. HHS is soliciting nominations of individuals for appointment to the Ethics Board for fiscal year 2020. Nominations for qualified individuals for appointment to the Ethics Board are currently being accepted.
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2020-03293
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting
Document Number: 2020-03290
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2020-03289
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2020-03288
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Cancellation of Meeting
Document Number: 2020-03286
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2020-03285
Type: Notice
Date: 2020-02-20
Agency: Department of Health and Human Services, National Institutes of Health
Medicaid Program; Preadmission Screening and Resident Review
Document Number: 2020-03081
Type: Proposed Rule
Date: 2020-02-20
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
This proposed rule would modernize the requirements for Preadmission Screening and Resident Review (PASRR), currently referred to in regulation as Preadmission Screening and Annual Resident Review, by incorporating statutory changes, reflecting updates to diagnostic criteria for mental illness and intellectual disability, reducing duplicative requirements and other administrative burdens on State PASRR programs, and making the process more streamlined and person- centered.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.